|
MechanismTXA2 synthase inhibitors |
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.JP |
First Approval Date27 Mar 1992 |
[Translation] Pharmacokinetic study of ozagrel hydrochloride tablets in humans
本试验的目的是在健康志愿受试者中研究通辽市华邦药业有限公司提供的盐酸奥扎格雷片,完成单次、多次给药药动学试验,通过建立血样中奥扎格雷及其代谢物的方法学和检测血浆样本,得到相应的药动学参数,了解盐酸奥扎格雷片在人体内动态变化的规律,多次连续给药体内蓄积情况,为临床合理用药提供依据。
[Translation] The purpose of this experiment is to study Ozagrel Hydrochloride Tablets provided by Tongliao Huabang Pharmaceutical Co., Ltd. in healthy volunteer subjects, complete the single and multiple administration pharmacokinetics test, and establish the ozagrel and ozagrel in blood samples. The methodology of its metabolites and the detection of plasma samples, to obtain the corresponding pharmacokinetic parameters, to understand the dynamic changes of ozagrel hydrochloride tablets in the human body, and to accumulate in vivo after multiple consecutive administrations, providing a basis for clinical rational drug use.
100 Clinical Results associated with Liaoning Sibaide Medicine Technology Co Ltd
0 Patents (Medical) associated with Liaoning Sibaide Medicine Technology Co Ltd
100 Deals associated with Liaoning Sibaide Medicine Technology Co Ltd
100 Translational Medicine associated with Liaoning Sibaide Medicine Technology Co Ltd